{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:28:58Z","timestamp":1787232538027,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Scientific Foundation of China","doi-asserted-by":"crossref","award":["No.81760751"],"award-info":[{"award-number":["No.81760751"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangxi Provincial Natural Scientific Foundation","award":["No. 2021GXNSFAA075020"],"award-info":[{"award-number":["No. 2021GXNSFAA075020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13806-5","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T10:16:19Z","timestamp":1781345779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of TDF+3TC\u2009+\u2009EFV\u2011centric antiretroviral regimens for HIV\/HBV co-infection: a systematic review and network meta\u2011analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Xinru","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuohua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"13806_CR1","unstructured":"Global HIV. & AIDS statistics \u2014 Fact sheet | UNAIDS. https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed 23 March 2026."},{"issue":"11","key":"13806_CR2","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/cid\/ciz1170","volume":"71","author":"S Leumi","year":"2020","unstructured":"Leumi S, Bigna JJ, Amougou MA, Ngouo A, Nyaga UF, Noubiap JJ. Global Burden of Hepatitis B Infection in People Living With Human Immunodeficiency Virus: A Systematic Review and Meta-analysis. Clin Infect Dis. 2020;71(11):2799\u2013806. https:\/\/doi.org\/10.1093\/cid\/ciz1170.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"13806_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1186\/s12879-024-09746-7","volume":"24","author":"M Shivakumar","year":"2024","unstructured":"Shivakumar M, Moe CA, Bardon A, et al. Hepatitis B prevalence and risk factors among adults living with HIV in South Africa: a clinic-based cohort study. BMC Infect Dis. 2024;24(1):891. https:\/\/doi.org\/10.1186\/s12879-024-09746-7.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"13806_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/00126334-200007010-00003","volume":"24","author":"M Puoti","year":"2000","unstructured":"Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000;24(3):211\u20137. https:\/\/doi.org\/10.1097\/00126334-200007010-00003.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"13806_CR5","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1097\/QAD.0b013e32835cb9c8","volume":"27","author":"C Hawkins","year":"2013","unstructured":"Hawkins C, Christian B, Ye J, et al. Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania. AIDS. 2013;27(6):919\u201327. https:\/\/doi.org\/10.1097\/QAD.0b013e32835cb9c8.","journal-title":"AIDS"},{"issue":"4","key":"13806_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11901-020-00541-x","volume":"19","author":"HN Kim","year":"2020","unstructured":"Kim HN, Chronic Hepatitis B, Coinfection HIV. A Continuing Challenge in the Era of Antiretroviral Therapy. Curr Hepatol Rep. 2020;19(4):345\u201353. https:\/\/doi.org\/10.1007\/s11901-020-00541-x.","journal-title":"Curr Hepatol Rep"},{"issue":"1","key":"13806_CR7","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1093\/cid\/ciaf281","volume":"82","author":"J Audsley","year":"2026","unstructured":"Audsley J, Avihingsanon A, Li X, et al. Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)-Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection. Clin Infect Dis. 2026;82(1):e176\u201384. https:\/\/doi.org\/10.1093\/cid\/ciaf281.","journal-title":"Clin Infect Dis"},{"key":"13806_CR8","doi-asserted-by":"publisher","unstructured":"Summary of 2021. Clinical guidelines for the diagnosis and treatment of HIV\/AIDS in HIV-infected Koreans. Infect Chemother. 2021;53(3). https:\/\/doi.org\/10.3947\/ic.2021.0305.","DOI":"10.3947\/ic.2021.0305"},{"issue":"11","key":"13806_CR9","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/hiv.13542","volume":"24","author":"J Ambrosioni","year":"2023","unstructured":"Ambrosioni J, Levi L, Alagaratnam J, et al. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med. 2023;24(11):1126\u201336. https:\/\/doi.org\/10.1111\/hiv.13542.","journal-title":"HIV Med"},{"key":"13806_CR10","unstructured":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization. 2013. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK195400\/. Accessed 23 March 2026."},{"issue":"4","key":"13806_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.19871\/j.cnki.xfcrbzz.2024.04.014","volume":"9","author":"Acquired Immunodeficiency Syndrome Professional Group, Society of Infectious Diseases, Chinese Medical Association","year":"2024","unstructured":"Acquired Immunodeficiency Syndrome Professional Group, Society of Infectious Diseases, Chinese Medical Association. Chinese Center for Disease Control, Prevention. Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection\/acquired immunodeficiency syndrome. Electron J Emerg Infect Dis. 2024;9(4):68. https:\/\/doi.org\/10.19871\/j.cnki.xfcrbzz.2024.04.014.","journal-title":"Electron J Emerg Infect Dis"},{"issue":"3","key":"13806_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jrsm.1195","volume":"7","author":"O Efthimiou","year":"2016","unstructured":"Efthimiou O, Debray TPA, van Valkenhoef G, et al. GetReal in network meta-analysis: a review of the methodology. Res Synth Methods. 2016;7(3):236\u201363. https:\/\/doi.org\/10.1002\/jrsm.1195.","journal-title":"Res Synth Methods"},{"key":"13806_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"05","key":"13806_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.13419\/j.cnki.aids.2018.05.06","volume":"24","author":"Y Liu","year":"2018","unstructured":"Liu Y, Li Z, Yang M. Meta-analysis of tenofovir combined with lamivudine in the treatment of HIV-HBV co-infection. Chin J AIDS STD. 2018;24(05):449\u201353. https:\/\/doi.org\/10.13419\/j.cnki.aids.2018.05.06.","journal-title":"Chin J AIDS STD"},{"issue":"1","key":"13806_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12985-018-1050-3","volume":"15","author":"A Luo","year":"2018","unstructured":"Luo A, Jiang X, Ren H. Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV\/HIV coinfection: a meta-analysis. Virol J. 2018;15(1):139. https:\/\/doi.org\/10.1186\/s12985-018-1050-3.","journal-title":"Virol J"},{"issue":"1","key":"13806_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1186\/s12879-025-10858-x","volume":"25","author":"J Yang","year":"2025","unstructured":"Yang J, Zhao X, Li F. INSTIs-centered antiviral regimens for first-line treatment of HIV\/AIDS: a network meta-analysis and cost-effectiveness analysis. BMC Infect Dis. 2025;25(1):604. https:\/\/doi.org\/10.1186\/s12879-025-10858-x.","journal-title":"BMC Infect Dis"},{"key":"13806_CR17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"07","key":"13806_CR18","first-page":"71","volume":"41","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Lv J, Zhang C, et al., et al. A network meta-analysis of Eleven Chinese Patent Medicines in the Treatment of Hypertensive Nephropathy. Pharmacol Clin Chin Materia. 2025;41(07):71\u201383.","journal-title":"Pharmacol Clin Chin Materia"},{"issue":"20","key":"13806_CR19","first-page":"6558","volume":"53","author":"Y Deng","year":"2022","unstructured":"Deng Y, Tan Y, Xie X, Qian Z, Zhang Y, Wang J. Network Meta-analysis of oral traditional Chinese medicine compound preparations combined with antiviral drugs in treatment of AIDS. Chin Traditional Herb Drugs. 2022;53(20):6558\u201372.","journal-title":"Chin Traditional Herb Drugs"},{"issue":"1","key":"13806_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/biom.13573","volume":"79","author":"Q Lian","year":"2023","unstructured":"Lian Q, Zhang J, Hodges JS, Chen Y, Chu H. Accounting for Post-randomization Variables in Meta-analysis: A Joint Meta-Regression Approach. Biometrics. 2023;79(1):358\u201367. https:\/\/doi.org\/10.1111\/biom.13573.","journal-title":"Biometrics"},{"issue":"22","key":"13806_CR21","doi-asserted-by":"publisher","first-page":"6198","DOI":"10.19540\/j.cnki.cjcmm.20240815.501","volume":"49","author":"SY Tao","year":"2024","unstructured":"Tao SY, Yu LT, Li J, et al. Network Meta-analysis of comparative efficacy of Chinese medicine injections for dilated cardiomyopathy. Zhongguo Zhong Yao Za Zhi. 2024;49(22):6198\u2013213. https:\/\/doi.org\/10.19540\/j.cnki.cjcmm.20240815.501.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"issue":"04","key":"13806_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.13664\/j.cnki.pcr.2024.04.023","volume":"32","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Xu D, Jin X, Sun Y. Network Meta-analysis of Six Chinese Patent Medicines in Treatment of Knee Osteoarthritis. Pharm Clin Res. 2024;32(04):338\u201342. https:\/\/doi.org\/10.13664\/j.cnki.pcr.2024.04.023.","journal-title":"Pharm Clin Res"},{"issue":"06","key":"13806_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.19613\/j.cnki.1671-3141.2019.06.091","volume":"19","author":"Y Deng","year":"2019","unstructured":"Deng Y. Clinical Effect of Tenofovir Disoproxil Combined with Lamivudine in the Treatment of AIDS Patients Coinfected with Hepatitis B Virus. World Latest Med Inform. 2019;19(06):180\u20132. https:\/\/doi.org\/10.19613\/j.cnki.1671-3141.2019.06.091.","journal-title":"World Latest Med Inform"},{"issue":"23","key":"13806_CR24","first-page":"172","volume":"25","author":"H Zhang","year":"2018","unstructured":"Zhang H, Fang G, Deng Q. Effect of Tenofovir combined with Lamivudine in the treatment of patients with Hepatitis B virus\/Human immunodeficiency virus co-infection. China Mod Med. 2018;25(23):172\u20134.","journal-title":"China Mod Med"},{"issue":"09","key":"13806_CR25","first-page":"992","volume":"26","author":"S Liu","year":"2017","unstructured":"Liu S. A 72-Week Efficacy Observation of Tenofovir and Lamivudine Combination Therapy in the Treatment of AIDS Complicated with Hepatitis B Virus Infection. Mod J Integr Traditional Chin Western Med. 2017;26(09):992\u20134.","journal-title":"Mod J Integr Traditional Chin Western Med"},{"issue":"07","key":"13806_CR26","first-page":"19","volume":"35","author":"X Da","year":"2019","unstructured":"Da X, Zhang R, Yu L. Clinical Efficacy of Tenofovir Disoproxil Combined with Lamivudine in the Treatment of AIDS Complicated with Hepatitis B Virus Infection. Chin Community Doctors. 2019;35(07):19\u201322.","journal-title":"Chin Community Doctors"},{"issue":"20","key":"13806_CR27","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.19381\/j.issn.1001-7585.2017.20.040","volume":"30","author":"S Yin","year":"2017","unstructured":"Yin S. Analysis of Clinical Effect of Tenofovir Disoproxil Combined with Lamivudine in the Treatment of AIDS Complicated with Hepatitis B Virus Infection. J Med Theory Pract. 2017;30(20):3045\u20136. https:\/\/doi.org\/10.19381\/j.issn.1001-7585.2017.20.040.","journal-title":"J Med Theory Pract"},{"issue":"08","key":"13806_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.19368\/j.cnki.2096-1782.2016.08.054","volume":"1","author":"H Gao","year":"2016","unstructured":"Gao H. Tenofovir and Lamivudine in Treatment of AIDS Complicated with Hepatitis B Virus Infection. Syst Med. 2016;1(08):54\u20136. https:\/\/doi.org\/10.19368\/j.cnki.2096-1782.2016.08.054.","journal-title":"Syst Med"},{"key":"13806_CR29","doi-asserted-by":"publisher","unstructured":"Yang K, Guo J. Observation of efficacy of tenofovir disoproxil fumarate combined with lamivudine in treatment of acquired immunodeficiency syndrome complicated with hepatitis B Virus infection. Eval Anal Drug Use Hos China. 2018;18(07):887\u20139. https:\/\/doi.org\/10.14009\/j.issn.1672-2124.2018.07.009.","DOI":"10.14009\/j.issn.1672-2124.2018.07.009"},{"issue":"05","key":"13806_CR30","first-page":"718","volume":"13","author":"H Xia","year":"2018","unstructured":"Xia H. Clinical effect of tenofovir dipivoxil combined with lamivudine on acquired immunodeficiency syndrome complicated with hepatitis B virus infection. China Med. 2018;13(05):718\u201320.","journal-title":"China Med"},{"issue":"02","key":"13806_CR31","first-page":"70","volume":"9","author":"G Ding","year":"2020","unstructured":"Ding G, Huang L, Li J. Observation of Efficacy of Tenofovir Disoproxil Combined with Lamivudine in the Treatment of AIDS Complicated with Hepatitis B Virus Infection. Int Infections Dis. 2020;9(02):70\u20131.","journal-title":"Int Infections Dis"},{"key":"13806_CR32","unstructured":"Zhu Q. Clinical Efficacy of tenofovir disoproxil and lamivudine combination therapy for AIDS complicated with hepatitis B virus infection. Med Health. 2016;(1):270."},{"issue":"33","key":"13806_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3969\/j.issn.1004-7484.2017.33.422","volume":"27","author":"C Li","year":"2017","unstructured":"Li C. Efficacy Analysis of Tenofovir Combined with Lamivudine in the Clinical Treatment of AIDS Complicated with Hepatitis B Virus Infection. China Health Care Nutr. 2017;27(33):267\u20138. https:\/\/doi.org\/10.3969\/j.issn.1004-7484.2017.33.422.","journal-title":"China Health Care Nutr"},{"issue":"30","key":"13806_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3969\/j.issn.2095-1752.2018.30.017","volume":"8","author":"R Yang","year":"2018","unstructured":"Yang R. Efficacy of tenofovir combined with lamivudine in treatment of AIDS merged with hepatitis B virus infection. J Front Med. 2018;8(30):25\u20136. https:\/\/doi.org\/10.3969\/j.issn.2095-1752.2018.30.017.","journal-title":"J Front Med"},{"issue":"A01","key":"13806_CR35","first-page":"0316","volume":"24","author":"Z Sun","year":"2019","unstructured":"Sun Z. Value Analysis of 72-Week Combination Therapy with Tenofovir and Lamivudine for AIDS Complicated with Hepatitis B Virus Infection. Mod Interventional Diagnosis Treat Gastroenterol. 2019;24(A01):0316\u20137.","journal-title":"Mod Interventional Diagnosis Treat Gastroenterol"},{"issue":"11","key":"13806_CR36","first-page":"347","volume":"30","author":"D Wang","year":"2020","unstructured":"Wang D. Clinical Analysis of Tenofovir Disoproxil Combined with Lamivudine in the Treatment of AIDS Complicated with Hepatitis B Virus Infection. China Health Care Nutr. 2020;30(11):347\u20138.","journal-title":"China Health Care Nutr"},{"issue":"36","key":"13806_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3969\/j.issn.1674-4721.2020.36.015","volume":"27","author":"J Wu","year":"2020","unstructured":"Wu J, Ao J, Liu P, Hu D. Effect of Tenofovir Dipivoxil combined with Lamivudine in the treatment of AIDS combined with hepatitis B virus infection. China Mod Med. 2020;27(36):49\u201351. https:\/\/doi.org\/10.3969\/j.issn.1674-4721.2020.36.015.","journal-title":"China Mod Med"},{"issue":"09","key":"13806_CR38","first-page":"1094","volume":"32","author":"W Huang","year":"2021","unstructured":"Huang W, Guo S, Zhang X. Clinical Efficacy Analysis of Tenofovir Disoproxil Combined with Lamivudine in the Treatment of AIDS Complicated with Hepatitis B Virus Infection. J Aerosp Med. 2021;32(09):1094\u20135.","journal-title":"J Aerosp Med"},{"issue":"6","key":"13806_CR39","first-page":"32","volume":"16","author":"R Wang","year":"2023","unstructured":"Wang R. Clinical Efficacy Analysis of Tenofovir Dipivoxil Combined with Lamivudine in the Treatment of AIDS Complicated with Hepatitis B Virus Infection. Family Pharmacist. 2023;16(6):32\u20134.","journal-title":"Family Pharmacist"},{"issue":"05","key":"13806_CR40","first-page":"68","volume":"17","author":"J Bai","year":"2018","unstructured":"Bai J. Clinical Effect of Tenofovir Disoproxil Combined with Lamivudine in the Treatment of Patients with AIDS Complicated with Hepatitis B Virus Infection. Health Way. 2018;17(05):68.","journal-title":"Health Way"},{"issue":"12","key":"13806_CR41","first-page":"149","volume":"22","author":"W YIN","year":"2019","unstructured":"YIN W, Zhu C. Efficacy Analysis of Tenofovir Disoproxil Combined with Lamivudine in the Treatment of AIDS Complicated with Hepatitis B Virus Infection. Sci Regimen. 2019;22(12):149\u201350.","journal-title":"Sci Regimen"},{"issue":"3","key":"13806_CR42","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1086\/314942","volume":"180","author":"GJ Dore","year":"1999","unstructured":"Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus\/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis. 1999;180(3):607\u201313. https:\/\/doi.org\/10.1086\/314942.","journal-title":"J Infect Dis"},{"issue":"5","key":"13806_CR43","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/hep.21388","volume":"44","author":"MG Peters","year":"2006","unstructured":"Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology. 2006;44(5):1110\u20136. https:\/\/doi.org\/10.1002\/hep.21388.","journal-title":"Hepatology"},{"issue":"31","key":"13806_CR44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3969\/j.issn.1007-614x.2021.31.034","volume":"37","author":"T Lu","year":"2021","unstructured":"Lu T. Comprehensive study on the efficacy and safety of tenofovir + lamivudine + efavirenz in the treatment of HBV\/HIV co-infection. Chin Community Doctors. 2021;37(31):73\u20134. https:\/\/doi.org\/10.3969\/j.issn.1007-614x.2021.31.034.","journal-title":"Chin Community Doctors"},{"issue":"08","key":"13806_CR45","first-page":"1497","volume":"31","author":"X Zhao","year":"2022","unstructured":"Zhao X, Zang K. Effect of Combined Tenofovir,Lamivudine,Efavirenz on Liver Function and HBV Virus Characteristic in HBV \/HIV Infected Patients. Henan Med Res. 2022;31(08):1497\u2013500.","journal-title":"Henan Med Res"},{"issue":"13","key":"13806_CR46","first-page":"146","volume":"22","author":"J Luo","year":"2016","unstructured":"Luo J, Chen B, Yang S, et al. Observation on the Efficacy of Antiviral Therapy in HIV Infection Complicated with Chronic Hepatitis B. Contemp Med. 2016;22(13):146\u20137.","journal-title":"Contemp Med"},{"issue":"02","key":"13806_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.15887\/j.cnki.13-1389\/r.2023.02.028","volume":"16","author":"P Yan","year":"2023","unstructured":"Yan P. Comparison of Efficacy between Tenofovir Disoproxil and Zidovudine as Adjuvant Therapy in Patients with AIDS Complicated with Hepatitis B Virus Infection. Chin J Clin Ration Drug Use. 2023;16(02):93\u20136. https:\/\/doi.org\/10.15887\/j.cnki.13-1389\/r.2023.02.028.","journal-title":"Chin J Clin Ration Drug Use"},{"key":"13806_CR48","unstructured":"CAI L. Efficacy of tenofovir combined with lamivudine in the treatment of hiv coinfected with HBV and its impact on patients\u2019 Immune Function. Strait Pharm J. 2018;30(11):84\u20136."},{"issue":"2","key":"13806_CR49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4103\/ijmm.IJMM_17_37","volume":"36","author":"J Sarkar","year":"2018","unstructured":"Sarkar J, Saha D, Bandyopadhyay B, Saha B, Chakravarty R, Guha SK. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy. Indian J Med Microbiol. 2018;36(2):217\u201323. https:\/\/doi.org\/10.4103\/ijmm.IJMM_17_37.","journal-title":"Indian J Med Microbiol"},{"issue":"7","key":"13806_CR50","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1086\/380398","volume":"189","author":"GJ Dore","year":"2004","unstructured":"Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189(7):1185\u201392. https:\/\/doi.org\/10.1086\/380398.","journal-title":"J Infect Dis"},{"issue":"02","key":"13806_CR51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.14033\/j.cnki.cfmr.2019.02.074","volume":"17","author":"M WU","year":"2019","unstructured":"WU M. Efficacy and Safety Evaluation of Tenofovir Disoproxil Combined with Lamivudine and Efavirenz in the Treatment of AIDS Complicated with Hepatitis B Virus Infection. Chin Foreign Med Res. 2019;17(02):147\u20138. https:\/\/doi.org\/10.14033\/j.cnki.cfmr.2019.02.074.","journal-title":"Chin Foreign Med Res"},{"key":"13806_CR52","doi-asserted-by":"publisher","unstructured":"ZHOU M. Efficacy and safety analysis of tenofovir disoproxil combined with lamivudine and efavirenz in the treatment of AIDS complicated with hepatitis B virus infection. Med Inform. 2016;29(32):50\u20131. https:\/\/doi.org\/10.3969\/j.issn.1006-1959.2016.32.033","DOI":"10.3969\/j.issn.1006-1959.2016.32.033"},{"issue":"4","key":"13806_CR53","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/hep.22462","volume":"48","author":"GV Matthews","year":"2008","unstructured":"Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV\/HBV coinfected antiretroviral na\u00efve individuals in Thailand. Hepatology. 2008;48(4):1062\u20139. https:\/\/doi.org\/10.1002\/hep.22462.","journal-title":"Hepatology"},{"issue":"3","key":"13806_CR54","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cld.2019.04.004","volume":"23","author":"DL Wyles","year":"2019","unstructured":"Wyles DL. Antiretroviral Effects on HBV\/HIV Co-infection and the Natural History of Liver Disease. Clin Liver Dis. 2019;23(3):473\u201386. https:\/\/doi.org\/10.1016\/j.cld.2019.04.004.","journal-title":"Clin Liver Dis"},{"issue":"1","key":"13806_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-1293.2009.00781.x","volume":"11","author":"G Brook","year":"2010","unstructured":"Brook G, Main J, Nelson M, et al. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med. 2010;11(1):1\u201330. https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00781.x.","journal-title":"HIV Med"},{"key":"13806_CR56","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2147\/JHC.S307962","volume":"8","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Han Q, Zhao H, Zhang J. The Mechanisms of HBV-Induced Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021;8:435\u201350. https:\/\/doi.org\/10.2147\/JHC.S307962.","journal-title":"J Hepatocell Carcinoma"},{"issue":"12","key":"13806_CR57","first-page":"1872","volume":"32","author":"J Wang","year":"2021","unstructured":"Wang J. Research Progress of Antiviral Therapy in Patients with Chronic Hepatitis B. Mod Diagnosis Treat. 2021;32(12):1872\u20131872.","journal-title":"Mod Diagnosis Treat"},{"issue":"1 Suppl","key":"13806_CR58","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","volume":"64","author":"M Levrero","year":"2016","unstructured":"Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1 Suppl):S84\u2013101. https:\/\/doi.org\/10.1016\/j.jhep.2016.02.021.","journal-title":"J Hepatol"},{"key":"13806_CR59","doi-asserted-by":"publisher","first-page":"115741","DOI":"10.1016\/j.bcp.2023.115741","volume":"215","author":"L Hruba","year":"2023","unstructured":"Hruba L, Das V, Hajduch M, Dzubak P. Nucleoside-based anticancer drugs: Mechanism of action and drug resistance. Biochem Pharmacol. 2023;215:115741. https:\/\/doi.org\/10.1016\/j.bcp.2023.115741.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"13806_CR60","doi-asserted-by":"publisher","first-page":"100574","DOI":"10.1016\/j.jve.2024.100574","volume":"10","author":"AM Mohareb","year":"2024","unstructured":"Mohareb AM, Miailhes P, Bottero J, et al. Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: Results from a prospective cohort study. J Virus Erad. 2024;10(4):100574. https:\/\/doi.org\/10.1016\/j.jve.2024.100574.","journal-title":"J Virus Erad"},{"key":"13806_CR61","unstructured":"Clinical Effect of Lamivudine, Tenofovir and efavirenz combined antiviral regimen in the treatment of AIDS. https:\/\/kns.cnki.net\/kcms2\/article\/abstract.\u00a0Accessed 23 March 2026."},{"issue":"3","key":"13806_CR62","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/QAD.0000000000003764","volume":"38","author":"M Lartey","year":"2024","unstructured":"Lartey M, Ganu VJ, Tachi K, et al. Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and hepatitis B virus viral suppression. AIDS. 2024;38(3):351\u201362. https:\/\/doi.org\/10.1097\/QAD.0000000000003764.","journal-title":"AIDS"},{"key":"13806_CR63","doi-asserted-by":"publisher","unstructured":"Adkins JC, Noble S E, Drugs. 1998;56(6):1055\u20131064; discussion 1065\u20131066. https:\/\/doi.org\/10.2165\/00003495-199856060-00014","DOI":"10.2165\/00003495-199856060-00014"},{"issue":"10","key":"13806_CR64","doi-asserted-by":"publisher","first-page":"145","DOI":"10.16286\/j.1003-5052.2023.10.053","volume":"38","author":"G Lin","year":"2023","unstructured":"Lin G, Fang G. Analysis of the dynamic changes of CD4+\/CD8 + after AIDS confirmed diagnosis. Chin J Urban Rural Enterp Hygiene. 2023;38(10):145\u20137. https:\/\/doi.org\/10.16286\/j.1003-5052.2023.10.053.","journal-title":"Chin J Urban Rural Enterp Hygiene"},{"issue":"1","key":"13806_CR65","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/ijstd.ijstd_44_21","volume":"44","author":"B Singh","year":"2023","unstructured":"Singh B, Guliani A, Hanumanthu V, et al. A prospective study to estimate the incidence and pattern of adverse drug reactions to first-line antiretroviral therapy (tenofovir, efavirenz, and lamivudine). Indian J Sex Transm Dis AIDS. 2023;44(1):6\u201310. https:\/\/doi.org\/10.4103\/ijstd.ijstd_44_21.","journal-title":"Indian J Sex Transm Dis AIDS"},{"issue":"9","key":"13806_CR66","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1093\/cid\/cit002","volume":"56","author":"GV Matthews","year":"2013","unstructured":"Matthews GV, Seaberg EC, Avihingsanon A, et al. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis. 2013;56(9):e87\u201394. https:\/\/doi.org\/10.1093\/cid\/cit002.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"13806_CR67","first-page":"3428","volume":"23","author":"Y LAN","year":"2025","unstructured":"LAN Y, MA K. Tenofovir Disoproxil Fumarate-Induced Hypophosphatemic Osteomalacia: A Case Report. Cent South Pharm. 2025;23(11):3428\u201330.","journal-title":"Cent South Pharm"},{"issue":"10","key":"13806_CR68","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1681\/ASN.2012080857","volume":"24","author":"J Tourret","year":"2013","unstructured":"Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013;24(10):1519\u201327. https:\/\/doi.org\/10.1681\/ASN.2012080857.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"13806_CR69","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1080\/17512433.2016.1221760","volume":"9","author":"JP Mouton","year":"2016","unstructured":"Mouton JP, Cohen K, Maartens G. Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen. Expert Rev Clin Pharmacol. 2016;9(11):1493\u2013503. https:\/\/doi.org\/10.1080\/17512433.2016.1221760.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"13806_CR70","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ijid.2022.01.051","volume":"117","author":"J Xiao","year":"2022","unstructured":"Xiao J, Xiao J, Liu Y, et al. Efficacy and safety of Efavirenz 400\u00a0mg-based regimens switching from 600\u00a0mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study. Int J Infect Dis. 2022;117:48\u201355. https:\/\/doi.org\/10.1016\/j.ijid.2022.01.051.","journal-title":"Int J Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13806-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:02:27Z","timestamp":1787230947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13806-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13806"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13806-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1541"}}